Physician profile
Troy Sterk
NPI 1023003258
$6,483.62
in general payments reported to CMS, 2019-2025
34 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2021: $188 · 2022: $1,281 · 2023: $1,570 · 2024: $1,358 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,577 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,576.90 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,475.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,011.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lucid Diagnostics INC. | $950.62 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $483.96 | 2021-2025 | |
| Lilly USA, LLC | $351.03 | 2022-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.28 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $319.94 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $164.84 | 2022-2025 | Nexletol, Contrave, Nexlizet |
| Janssen Pharmaceuticals, INC | $162.50 | 2022-2023 | Xarelto |
| Abbott Laboratories | $131.19 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $130.30 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $110.83 | 2021-2023 | Unithroid |
| Organogenesis INC. | $110.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $100.24 | 2019-2025 | |
| Alk-Abello, INC | $88.93 | 2024-2025 | Odactra, Grastek, Neffy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.10 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $52.34 | 2022 | |
| Merck Sharp & Dohme LLC | $45.09 | 2019-2022 | |
| Exact Sciences Corporation | $44.73 | 2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $42.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.04 | 2023-2025 | Xifaxan, Ibschek |
| Dexcom, INC. | $31.36 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $30.56 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.92 | 2019-2025 | Lifevest |
| Photonicare INC | $27.54 | 2025 | Otosight Middle Ear Scope |
| Surgenex LLC | $22.75 | 2025 | Pellograft, Ardeograft, Surgraft |
| Eisai INC. | $18.59 | 2021 | |
| Genentech USA, INC. | $16.80 | 2021 | |
| Glaxosmithkline, LLC. | $16.71 | 2023 | Trelegy Ellipta |
| Fidia Pharma USA INC. | $16.53 | 2025 | Hymovis, Triluron |
| Axonics, INC. | $16.44 | 2023 | Axonics, Bulkamid |
| Mylan Specialty L.P. | $16.33 | 2019 | |
| Endo Pharmaceuticals INC. | $16.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Sterk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.